Rebecca Zash1, Lewis Holmes1, Modiegi Diseko1, Denise L Jacobson1, Sean Brummel1, Gloria Mayondi1, Arielle Isaacson1, Sonya Davey1, Judith Mabuta1, Mompati Mmalane1, Tendani Gaolathe1, M Essex1, Shahin Lockman1, Joseph Makhema1, Roger L Shapiro1. 1. From the Division of Infectious Diseases, Beth Israel Deaconess Medical Center (R.Z., R.L.S.), the Department of Immunology and Infectious Diseases (R.Z., M.E., S.L., J. Makhema, R.L.S.) and the Center for Biostatistics in AIDS Research (D.L.J., S.B.), Harvard T.H. Chan School of Public Health, MassGeneral Hospital for Children, Massachusetts General Hospital (L.H.), and the Division of Infectious Diseases, Brigham and Women's Hospital (S.L.) - all in Boston; the Botswana-Harvard AIDS Institute Partnership (R.Z., M.D., G.M., A.I., S.D., J. Mabuta, M.M., T.G., M.E., S.L., J. Makhema, R.L.S.) and the University of Botswana Faculty of Medicine (T.G.), Gaborone, Botswana; and the University of Pennsylvania Perelman School of Medicine, Philadelphia (S.D.).
Abstract
BACKGROUND: A preliminary safety signal for neural-tube defects was previously reported in association with dolutegravir exposure from the time of conception, which has affected choices of antiretroviral treatment (ART) for human immunodeficiency virus (HIV)-infected women of reproductive potential. The signal can now be evaluated with data from follow-up of additional pregnancies. METHODS: We conducted birth-outcomes surveillance at hospitals throughout Botswana, expanding from 8 to 18 sites in 2018. Trained midwives performed surface examinations of all live-born and stillborn infants. Research assistants photographed abnormalities after maternal consent was obtained. The prevalence of neural-tube defects and major external structural defects according to maternal HIV infection and ART exposure status was determined. In the primary analyses, we used the Newcombe method to evaluate differences in prevalence with 95% confidence intervals. RESULTS: From August 2014 through March 2019, surveillance captured 119,477 deliveries; 119,033 (99.6%) had an infant surface examination that could be evaluated, and 98 neural-tube defects were identified (0.08% of deliveries). Among 1683 deliveries in which the mother was taking dolutegravir at conception, 5 neural-tube defects were found (0.30% of deliveries); the defects included two instances of myelomeningocele, one of anencephaly, one of encephalocele, and one of iniencephaly. In comparison, 15 neural-tube defects were found among 14,792 deliveries (0.10%) in which the mother was taking any non-dolutegravir ART at conception, 3 among 7959 (0.04%) in which the mother was taking efavirenz at conception, 1 among 3840 (0.03%) in which the mother started dolutegravir treatment during pregnancy, and 70 among 89,372 (0.08%) in HIV-uninfected mothers. The prevalence of neural-tube defects was higher in association with dolutegravir treatment at conception than with non-dolutegravir ART at conception (difference, 0.20 percentage points; 95% confidence interval [CI], 0.01 to 0.59) or with other types of ART exposure. Major external structural defects were found in 0.95% of deliveries among women exposed to dolutegravir at conception and 0.68% of those among women exposed to non-dolutegravir ART at conception (difference, 0.27 percentage points; 95% CI, -0.13 to 0.87). CONCLUSIONS: The prevalence of neural-tube defects was slightly higher in association with dolutegravir exposure at conception than with other types of ART exposure at conception (3 per 1000 deliveries vs. 1 per 1000 deliveries). (Funded by the National Institutes of Health.).
BACKGROUND: A preliminary safety signal for neural-tube defects was previously reported in association with dolutegravir exposure from the time of conception, which has affected choices of antiretroviral treatment (ART) for human immunodeficiency virus (HIV)-infected women of reproductive potential. The signal can now be evaluated with data from follow-up of additional pregnancies. METHODS: We conducted birth-outcomes surveillance at hospitals throughout Botswana, expanding from 8 to 18 sites in 2018. Trained midwives performed surface examinations of all live-born and stillborn infants. Research assistants photographed abnormalities after maternal consent was obtained. The prevalence of neural-tube defects and major external structural defects according to maternal HIV infection and ART exposure status was determined. In the primary analyses, we used the Newcombe method to evaluate differences in prevalence with 95% confidence intervals. RESULTS: From August 2014 through March 2019, surveillance captured 119,477 deliveries; 119,033 (99.6%) had an infant surface examination that could be evaluated, and 98 neural-tube defects were identified (0.08% of deliveries). Among 1683 deliveries in which the mother was taking dolutegravir at conception, 5 neural-tube defects were found (0.30% of deliveries); the defects included two instances of myelomeningocele, one of anencephaly, one of encephalocele, and one of iniencephaly. In comparison, 15 neural-tube defects were found among 14,792 deliveries (0.10%) in which the mother was taking any non-dolutegravir ART at conception, 3 among 7959 (0.04%) in which the mother was taking efavirenz at conception, 1 among 3840 (0.03%) in which the mother started dolutegravir treatment during pregnancy, and 70 among 89,372 (0.08%) in HIV-uninfected mothers. The prevalence of neural-tube defects was higher in association with dolutegravir treatment at conception than with non-dolutegravir ART at conception (difference, 0.20 percentage points; 95% confidence interval [CI], 0.01 to 0.59) or with other types of ART exposure. Major external structural defects were found in 0.95% of deliveries among women exposed to dolutegravir at conception and 0.68% of those among women exposed to non-dolutegravir ART at conception (difference, 0.27 percentage points; 95% CI, -0.13 to 0.87). CONCLUSIONS: The prevalence of neural-tube defects was slightly higher in association with dolutegravir exposure at conception than with other types of ART exposure at conception (3 per 1000 deliveries vs. 1 per 1000 deliveries). (Funded by the National Institutes of Health.).
Authors: José Villar; Francesca Giuliani; Tanis R Fenton; Eric O Ohuma; Leila Cheikh Ismail; Stephen H Kennedy Journal: Lancet Date: 2016-02-18 Impact factor: 79.321
Authors: Robert M Cabrera; Jaclyn P Souder; John W Steele; Lythou Yeo; Gabriel Tukeman; Daniel A Gorelick; Richard H Finnell Journal: AIDS Date: 2019-11-01 Impact factor: 4.177
Authors: Rebecca Zash; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Mompati Mmalane; Max Essex; Tendani Gaolethe; Chipo Petlo; Shahin Lockman; Lewis B Holmes; Joseph Makhema; Roger L Shapiro Journal: Lancet Glob Health Date: 2018-06-04 Impact factor: 26.763
Authors: Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn Journal: Expert Rev Clin Pharmacol Date: 2019-12 Impact factor: 5.045
Authors: Abhinav Ajaykumar; Mayanne Zhu; Fatima Kakkar; Jason Brophy; Ari Bitnun; Ariane Alimenti; Hugo Soudeyns; Sara Saberi; Arianne Y K Albert; Deborah M Money; Hélène C F Côté Journal: J Infect Dis Date: 2021-02-24 Impact factor: 5.226
Authors: Claudia S Crowell; Paige L Williams; Cenk Yildirim; Russell B Van Dyke; Renee Smith; Ellen G Chadwick; George R Seage; Alexandria Diperna; Rohan Hazra Journal: AIDS Date: 2020-07-15 Impact factor: 4.177
Authors: Katherine B Rucinski; Kimberly A Powers; Audrey E Pettifor; Vivian Black; Brian W Pence; Benjamin H Chi; Helen Rees; Sheree R Schwartz Journal: AIDS Care Date: 2020-02-02